LLY

1,024.57

-1%↓

JNJ

239.44

+0.34%↑

ABBV

221.29

-1.57%↓

NVS

159.45

+1.04%↑

MRK

118.56

+1.51%↑

LLY

1,024.57

-1%↓

JNJ

239.44

+0.34%↑

ABBV

221.29

-1.57%↓

NVS

159.45

+1.04%↑

MRK

118.56

+1.51%↑

LLY

1,024.57

-1%↓

JNJ

239.44

+0.34%↑

ABBV

221.29

-1.57%↓

NVS

159.45

+1.04%↑

MRK

118.56

+1.51%↑

LLY

1,024.57

-1%↓

JNJ

239.44

+0.34%↑

ABBV

221.29

-1.57%↓

NVS

159.45

+1.04%↑

MRK

118.56

+1.51%↑

LLY

1,024.57

-1%↓

JNJ

239.44

+0.34%↑

ABBV

221.29

-1.57%↓

NVS

159.45

+1.04%↑

MRK

118.56

+1.51%↑

Home・Aandelen Lijst・Celsion Corp

Celsion Corp

Open

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken
By Trading Economics
Werknemers	25

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+470.99% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	938K
Vorige openingsprijs	0
Vorige sluitingsprijs	0

Celsion Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 feb 2026, 23:26 UTC

Belangrijke Marktbewegers

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10 feb 2026, 22:31 UTC

Winsten

Correction to America Movil 4Q Profit Article

10 feb 2026, 22:22 UTC

Winsten

America Movil 4Q Profit Jumps on Lower Financial Costs

10 feb 2026, 23:51 UTC

Marktinformatie

Winsten

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10 feb 2026, 23:42 UTC

Marktinformatie

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10 feb 2026, 23:40 UTC

Marktinformatie

Winsten

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10 feb 2026, 23:21 UTC

Marktinformatie

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10 feb 2026, 23:21 UTC

Marktinformatie

Global Equities Roundup: Market Talk

10 feb 2026, 22:17 UTC

Marktinformatie

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10 feb 2026, 22:15 UTC

Winsten

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10 feb 2026, 22:10 UTC

Winsten

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10 feb 2026, 22:10 UTC

Winsten

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10 feb 2026, 22:09 UTC

Winsten

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10 feb 2026, 22:09 UTC

Winsten

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10 feb 2026, 22:01 UTC

Winsten

Intact Financial 4Q EPS C$5.24 >IFC.T

10 feb 2026, 21:54 UTC

Winsten

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10 feb 2026, 21:53 UTC

Winsten

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10 feb 2026, 21:51 UTC

Winsten

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10 feb 2026, 21:51 UTC

Winsten

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 feb 2026, 21:51 UTC

Winsten

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10 feb 2026, 21:51 UTC

Winsten

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10 feb 2026, 21:51 UTC

Winsten

Acquisities, Fusies, Overnames

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10 feb 2026, 21:50 UTC

Winsten

Acquisities, Fusies, Overnames

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10 feb 2026, 21:50 UTC

Winsten

James Hardie Industries 3Q EPS 12c >JHX

10 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

10 feb 2026, 21:50 UTC

Winsten

James Hardie Industries 3Q Adj EPS 24c >JHX

10 feb 2026, 21:49 UTC

Winsten

James Hardie Industries 3Q Sales $1.24B >JHX

10 feb 2026, 21:49 UTC

Winsten

Acquisities, Fusies, Overnames

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10 feb 2026, 21:48 UTC

Winsten

Acquisities, Fusies, Overnames

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10 feb 2026, 21:47 UTC

Winsten

Acquisities, Fusies, Overnames

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Peer Vergelijking

Prijswijziging

Celsion Corp Prognose

Koersdoel

By TipRanks

470.99% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.5 USD 470.99%

Hoogste 25 USD

Laagste 12 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celsion Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Celsion Corp - Dist in de afgelopen 3 maanden.

Financieel

Over Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.